Besides, brain metastases are common in EGFR‐mutated NSCLC patients, with 25% of newly diagnosed patients having brain metastases at diagnosis, with nearly half developing them during the disease course [5, 6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.